BioMarin Pharmaceutical Inc. Share Price & Technical Analysis
BMRN · $54.09 (-0.02%)
Healthcare / Biotechnology
$54.09
-0.02%
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV ty…
Price chart
Seasonality
May has 1 positive and 4 negative years (last 5 years shown)
0% return in May, -8% avg return in past 3 year May month.
-7% return in 2026, -14% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -5% | 9% | -7% | -5% | 0% | – | – | – | – | – | – | – | -7% |
| 25 | -4% | 14% | -1% | -10% | -8% | -5% | 6% | 1% | -7% | -1% | 5% | 7% | -2% |
| 24 | -9% | -2% | 1% | -7% | -7% | 9% | 2% | 8% | -23% | -7% | 0% | 0% | -34% |
| 23 | 12% | -13% | -3% | -1% | -10% | -1% | 2% | 5% | -4% | -8% | 11% | 6% | -4% |
| 22 | 1% | -12% | -1% | 5% | -7% | 10% | 4% | 4% | -5% | 1% | 16% | 3% | 19% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Downtrend · Uptrend
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$10.19B
P/E ratio
37.91
52W high
$66.28
52W low
$49.26
Volume
24,38,349
Beta
0.23
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is BioMarin Pharmaceutical Inc. share price today?
- BioMarin Pharmaceutical Inc. (BMRN) last traded around $54.09 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does BMRN have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for BMRN. Download the app for real-time alerts.
- How can I analyze BioMarin Pharmaceutical Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.